In recent years,[1] patients with advanced lung cancer now have much better survival owing to using epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),[2,3] ushering in a new era of individualized therapy for lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.